Stock-based compensation increased 62.1%
Stock-based compensation changed +62.1% from the comparable as-filed period.
$5.4M→$8.8M3 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →AXGN financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Gross profit increased 23.3%
Gross profit changed +23.3% from the comparable as-filed period.
$46.0M→$56.7M2 prior comparisons
Inventory increased 20.9%
Inventory changed +20.9% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
$40.6M→$49.1M4 prior comparisons
SBC / revenue moved 257 bp higher
SBC / revenue changed +257 basis points from the comparable as-filed period.
9.03%→11.60%2 prior comparisons
Receivables / revenue moved 638 bp lower
Receivables / revenue changed -638 basis points from the comparable as-filed period.
51.22%→44.85%2 prior comparisons
Research & development increased 18.3%
Research & development changed +18.3% from the comparable as-filed period.
$7.6M→$9.0M2 prior comparisons
Trade receivables increased 10.5%
Trade receivables changed +10.5% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
$30.8M→$34.0M4 prior comparisons
Free-cash-flow margin moved 1714 bp higher
Free-cash-flow margin changed +1714 basis points from the comparable as-filed period.
2.83%→19.97%2 prior comparisons
Operating cash flow / net income increased 55.6%
Operating cash flow / net income changed +55.6% from the comparable as-filed period.
4.55→7.080 prior comparisons
Operating cash-flow margin moved 1644 bp higher
Operating cash-flow margin changed +1644 basis points from the comparable as-filed period.
5.36%→21.81%2 prior comparisons
Capex / revenue moved 69 bp lower
Capex / revenue changed -69 basis points from the comparable as-filed period.
2.53%→1.84%2 prior comparisons
R&D / revenue moved 79 bp lower
R&D / revenue changed -79 basis points from the comparable as-filed period.
12.59%→11.80%2 prior comparisons
Capital expenditure decreased 8.4%
Capital expenditure changed -8.4% from the comparable as-filed period.
$1.5M→$1.4M2 prior comparisons
Research & development increased 25.3%
Research & development changed +25.3% from the comparable as-filed period.
$6.9M→$8.6M2 prior comparisons
SBC / revenue moved 345 bp higher
SBC / revenue changed +345 basis points from the comparable as-filed period.
9.12%→12.57%2 prior comparisons
Gross profit increased 20.6%
Gross profit changed +20.6% from the comparable as-filed period.
$42.0M→$50.7M2 prior comparisons
Operating income changed across a sign change
Operating income changed -228.9% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
$1.7M→-$2.2M2 prior comparisons
Operating cash-flow margin moved 329 bp lower
Operating cash-flow margin changed -329 basis points from the comparable as-filed period.
13.64%→10.36%2 prior comparisons
Free-cash-flow margin moved 329 bp lower
Free-cash-flow margin changed -329 basis points from the comparable as-filed period.
12.37%→9.07%2 prior comparisons
Capital expenditure increased 23.7%
Capital expenditure changed +23.7% from the comparable as-filed period.
$722,000→$893,0003 prior comparisons
Net income changed across a sign change
Net income changed -361.8% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
$579,000→-$1.5M2 prior comparisons
Free-cash-flow proxy decreased 9.7%
Free-cash-flow proxy changed -9.7% from the comparable as-filed period.
$7.0M→$6.3M3 prior comparisons
Operating cash flow decreased 6.6%
Operating cash flow changed -6.6% from the comparable as-filed period.
$7.7M→$7.2M3 prior comparisons
Capex / revenue moved 1 bp higher
Capex / revenue changed +1 basis points from the comparable as-filed period.
1.27%→1.28%2 prior comparisons
Receivables / revenue moved 53 bp lower
Receivables / revenue changed -53 basis points from the comparable as-filed period.
49.47%→48.94%2 prior comparisons
R&D / revenue moved 22 bp higher
R&D / revenue changed +22 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
12.09%→12.32%2 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.